nonsmall

Inc., the oral drug did reach its secondary goal of so-called progression-free survival where the disease didn't get worse in patients with nonsquamous, nonsmall-cell lung cancer, Bayer said.

Corporate Watch 2010

Bayer estimates that 1.4 million people world-wide are diagnosed with lung cancer every year, and about 160,000 in the U.S. and 342,000 in Europe die from nonsmall-cell lung cancer annually.

Bayer Cancer Drug Fails to Meet Primary Goal 2010

Woburn, Mass., biotechnology company ArQule soared 2.22, or 63%, to 5.72, after its anticancer treatment candidate, in combination with another drug, showed a two-thirds improvement in progression-free survival for patients with advanced nonsmall-cell lung cancer.

Gulf Island, Seahawk Gain on Drilling News as Small Caps Fall Kristina Peterson 2010

Woburn, Mass., biotechnology company ArQule soared 2.22, or 63%, to 5.72, after its anticancer treatment candidate, in combination with another drug, showed a two-thirds improvement in progression-free survival for patients with advanced nonsmall-cell lung cancer.

Gulf Island, Seahawk Gain on Drilling News as Small Caps Fall Kristina Peterson 2010

Inc., the oral drug did reach its secondary goal of so-called progression-free survival where the disease didn't get worse in patients with nonsquamous, nonsmall-cell lung cancer, Bayer said.

Bayer Cancer Drug Fails to Meet Primary Goal 2010

Woburn, Mass., biotechnology company ArQule soared 2.22, or 63%, to 5.72, after its anticancer treatment candidate, in combination with another drug, showed a two-thirds improvement in progression-free survival for patients with advanced nonsmall-cell lung cancer.

Gulf Island, Seahawk Gain on Drilling News as Small Caps Fall Kristina Peterson 2010

Abbott Laboratories to develop a diagnostic test to screen patients with nonsmall-cell lung cancer for the presence of alterations in the ALK gene.

New Pfizer Drug Shrinks Some Lung-Cancer Tumors 2010

OSI Pharmaceuticals rose 8.3% after a Phase III study of Tarceva showed improvement in survival when used after initial chemotherapy in patients with advanced nonsmall cell lung cancer.

Dow Climbs 2.3% in Broad Rally 2009

Another drug in Amgen's pipeline, motesanib, suffered a setback in November, when a trial was suspended because of higher death rates in late-stage nonsmall-cell lung-cancer patients.

Amgen's Net Profit Increases 15% 2009

AstraZeneca said a Phase II study of the use of Recentin in nonsmall-cell lung cancer won't progress into Phase III after failing to meet its main goal.

AstraZeneca Ends 2008